Tino Hammer

MDTB Cells develops and GMP‑manufactures off‑the‑shelf umbilical‑cord‑derived MSC drugs — Desacell® and DEAGE® — for clinical development in sepsis, other inflammation‑associated conditions and age‑related diseases. The company combines a patented isolation process for low‑passage UC‑MSCs with industrialized GMP production, standardized CMC and potency assays to deliver clinical‑grade drug substance and drug product at scale. MDTB’s platform is built to remove supply bottlenecks for high‑dose allogeneic cell therapy: rapid clinical supply, reproducible batch‑to‑batch quality, and a tech‑transfer pathway to regional GMP partners. The product strategy targets immediate clinical impact in acute inflammatory indications (notably sepsis) while enabling longer‑term programs aimed at healthy‑life extension and age‑related indications (Vision: Longevity).